Global Sepsis Diagnostics Market Research Report 2022-2026 - Some Players have Already Made their Mark but Disruptive Diagnostic Technology Could Change the Playing Field

20 Jun 2022
www.prnewswire.com
Collaborate
DUBLIN, June 20, 2022 /PRNewswire/ -- The "Sepsis Diagnostics Global Markets by Assay, by Cause, by Product, by Lab, and by Place. With Executive and Consultant Guides and Sepsis Market Analysis and Forecasts 2022 - 2026" report has been added to
ResearchAndMarkets.com's offering.
The report forecasts the market size out to 2026. Growth is coming from the basic factors but the COVID-19 pandemic has changed to the market landscape now and for the foreseeable future.
Over 45 million people a year suffer from sepsis and there is no definitive diagnosis. The race is on using all the genomic and molecular diagnostic tools that have come to the fore in the last decade. It is not clear who will be the winner, but the stakes are global and large.
Emergency life-saving diagnostics can command a premium in the market, especially deaths related to COVID infections. Understand the different drivers of this huge global diagnostic market and find where the opportunities lie.
Some players have already made their mark but disruptive diagnostic technology could change the playing field. Learn about this market including the issues and outlooks.
The two key trends of Rapid Diagnostics and the Genomics Revolution are merging to create new diagnostic opportunities.
Sepsis - Current Science
What is Sepsis?
Organ Damage
Prognosis
Diagnosis
Biomarkers
Differential diagnosis
The Cytokine Storm - Diagnostic Needs
Causes of Sepsis
The Cytokine Storm - COVID and Other Situations
Prevalence
Impact of COVID on Sepsis Prevalence
Sepsis DiagnosticsSepsis Diagnostics - Recent Developments
Cytovale Prepping Sepsis Test for FDA Submission
Great North R & I to Develop POC Sepsis Dx
Pathogenomix Developing Sepsis Testing Platform
Gradientech Launches Study of AST System
Sepsis Test Developers Accelerate Plans
Immunexpress Receives Clearance for Sepsis Assay
Prenosis, Roche Partner on Sepsis Detection
Presymptom Health Developing Test for Sepsis
Ortho Clinical Diagnostics Interleukin-6 Reagent Pack
Cytovale to Enter Sepsis Testing Market
Baebies Awarded $11.6M to Develop Diagnostic Platform to ID Sepsis
Personalized Medicine in Sepsis
Point-of-care Device can Diagnose Sepsis in 30 Minutes
SpeeDx Developing Respiratory Virus Host-Response Test
Scanogen Developing Blood Infection Test with Sepsis Application
Inflammatix Developing New Sepsis Dx
Immunexpress, Biocartis to Roll Out Sepsis Test
Sepset Biosciences Using COVID-19 Patient Samples to Validate Sepsis Test
Immunexpress to Develop Sepsis Test
DNAe Developing POC Sequencing for Sepsis
NGS technique offers quick, accurate diagnosis of Sepsis
Portable device diagnoses sepsis faster
Ontera and QuantuMDx Collaborate on Sepsis Dx
Blood Test Accurately Predicts Sepsis Severity
BARDA/ HHS to support Cytovale rapid test
Mologic Developing Sepsis Test withMultimarker
Abionic: Diagnosis of Sepsis in 5 Minutes
T2 Biosystems Updates Rapid Diagnostic
Sepsis found to fit into 4 Subtypes
GenMark Diagnostics Receives Clearance for Blood Panel
Novacyt, Immunexpress Extend Sepsis Dx Partnership
New Test Could Diagnose Sepsis Faster
Immunexpress Wins $745K HHS Contract for Rapid Sepsis Assay
Curetis' Unyvero Cartridges Receive Approvals
Experimental 2.5-minute Sepsis Test Discovered
Septec Team Working on 15 Minute Sepsis Diagnosis
Profiles of Key Companies
Beckman Coulter Diagnostics
Becton, Dickinson and Company
Biocartis
Cube DX
DNAe
Response Biomedical
Roche Molecular Diagnostics
Septec
Players in a Dynamic Market
Academic Research Lab
Diagnostic Test Developer
Pharmaceutical/Reagent Supplier
Public National/regional lab
Hospital lab
Audit Body
Certification Body
Market Trends
Factors Driving Growth
Increasing Prevalence
Increasing Diagnosis
The Aging World
The Cost Curve Shrinks the Market
The Diagnostics Dilemma
Adoption Lag and Cost Control
Diagnostic Technology Development
The Multiplex Opportunity
Shifting Role of Physicians in Diagnosis
Diagnostics Moves Out of the Lab
Biomarkers and Algorithms
Rapid Testing Changing Medical Practice
Genome Role and Big Data
The Next Five Years
For more information about this report visit https://www.researchandmarkets.com/r/y22t52
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.